

Priti Hegde, Ph.D.
Global Franchise Biomarker Lead
Genentech
USA

Title: Overcoming Challenges in Drug Development in the Era of Cancer Immunotherapy

Abstract:

With over 1000 clinical trials ongoing with cancer immunotherapy combinations worldwide, conduct of clinical trials and comparison of data to historical controls is increasingly becoming a hurdle. In addition, the approval of cancer immunotherapies and combinations may pose a challenge for patients and treating physicians to identify the right drug or combination for their specific disease. Advances in molecular testing of patient tumors have vastly improved our ability to make educated decisions on patient enrollment in trials. In addition, registration of diagnostic tests in parallel to registration of trials will allow for tailored therapies for patients. These advances in parallel drug and diagnostic development strategies and the challenges with doing the same will be discussed.